PRECIGEN Investors


62nd American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 07, 2020 at 7:00 AM - 3:30 PM PST

Precigen presented abstract entitled "A Phase 1/1b Safety Study of PRGN-3006 UltraCAR-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome." (Abstract 2864)

Supporting Materials